Phase III trial of Tecentriq in NSCLC meets DFS primary endpoint

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

In 1999, Richard Pazdur, a GI oncologist at MD Anderson, saw an FDA recruitment ad in The New England Journal of Medicine. The agency was looking for a director of the FDA Division of Oncology Drug Products.

January 10, 2025

Vol.51 No.01

By Paul Goldberg

As fire encroached, City of Hope prepared to evacuate its Duarte campus

On Jan. 7, a bit after 6 p.m., Ravi Salgia was at his Eaton Canyon home, at the edge of Angeles National Forest.

Fran Visco awarded the Presidential Citizens Medal: “We are not going to change what we do or how we do it.”

Credit for photos: White HouseIn 1992, 44-year old Philly trial lawyer and breast cancer survivor, Fran Visco, took the stand before the Senate Labor, HHS, Education Appropriations Subcommittee, asserting a tone and stance previously unfamiliar in the world of cancer groups asking for funding before Congress.

January 10, 2025

Vol.51 No.01

By Claire Marie Porter

Capitol Hill

Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills

On Saturday, Dec. 21, Congress passed a new spending package, narrowly averting a government shutdown.

January 10, 2025

Vol.51 No.01

By Claire Marie Porter

Clinical Trials & Tribulations

New colorectal cancer screening strategies must advance the standard of care

Colorectal cancer is the second leading cause of cancer-related death in the United States. Accurate and early detection of CRC and precancerous lesions is critical for reducing incidence and preventing deaths from this disease.

53 Nobel Prizes and counting: ACS celebrates a legacy of funding research

In a new article on the Cancer History Project, the American Cancer Society profiles three ACS-funded Nobel laureates: David Baker, PhD2024 Nobel PrizeChemistry Victor Ambrose, PhD 2024 Nobel Prize Physiology or Medicine Gary Ruvkun, PhD2024 Nobel Prize Physiology or Medicine They join a cohort of 50 other ACS-funded Nobel laureates. “The American Cancer Society’s legacy, with 53 Nobel...

January 10, 2025

Vol.51 No.01

Phase III trial of Tecentriq in NSCLC meets DFS primary endpoint

YOU MAY BE INTERESTED IN

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

As fire encroached, City of Hope prepared to evacuate its Duarte campus

Fran Visco awarded the Presidential Citizens Medal: “We are not going to change what we do or how we do it.”

Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills

New colorectal cancer screening strategies must advance the standard of care

53 Nobel Prizes and counting: ACS celebrates a legacy of funding research

Renew today!

Subscriber content

Never miss an issue!

Login

Phase III trial of Tecentriq in NSCLC meets DFS primary endpoint

YOU MAY BE INTERESTED IN

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

As fire encroached, City of Hope prepared to evacuate its Duarte campus

Fran Visco awarded the Presidential Citizens Medal: “We are not going to change what we do or how we do it.”

Pediatric cancer research cut from spending legislation at last minuteRepublicans quietly removed hard-won pediatric cancer bills

New colorectal cancer screening strategies must advance the standard of care

53 Nobel Prizes and counting: ACS celebrates a legacy of funding research

Never miss an issue!

Login

Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills